Patents by Inventor Christopher Ronald Smith

Christopher Ronald Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS G12C INHIBITORS
    Publication number: 20200331911
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Inventors: Matthew Arnold Marx, James Gail Christensen, Christopher Ronald Smith, John P. Fischer, Aaron Craig Burns
  • KRAS G12C INHIBITORS
    Publication number: 20200308170
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 7, 2020
    Publication date: October 1, 2020
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • KRAS G12C INHIBITORS
    Publication number: 20200262837
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • KRas G12C inhibitors
    Patent number: 10689377
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: June 23, 2020
    Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell, John P. Fischer, Matthew Arnold Marx, Macedonio J. Mejia, Pavel Savechenkov, Guy P. A. Vigers, Christopher Ronald Smith, Martha E. Rodriguez
  • ASK1 isoindolin-1-one inhibitors and methods of use thereof
    Patent number: 10654833
    Abstract: Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes).
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 19, 2020
    Assignee: Hepatikos Therapeutics, LLC
    Inventors: Christopher Ronald Smith, Justin Chapman
  • KRas G12C inhibitors
    Patent number: 10647715
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 12, 2020
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200002312
    Abstract: Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes).
    Type: Application
    Filed: June 28, 2019
    Publication date: January 2, 2020
    Inventors: Christopher Ronald Smith, Justin Chapman
  • KRAS G12C INHIBITORS
    Publication number: 20190270743
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • KRAS G12C INHIBITORS
    Publication number: 20190144444
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: November 14, 2018
    Publication date: May 16, 2019
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell, John P. Fischer, Matthew Arnold Marx, Macedonio J. Mejia, Pavel Savechenkov, Guy P.A. Vigers, Christopher Ronald Smith, Martha E. Rodriguez
  • Bicyclic triazoles as protein kinase modulators
    Patent number: 8507489
    Abstract: The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: August 13, 2013
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: Pierre-Yves Bounaud, Christopher Ronald Smith, Elizabeth Anne Jefferson
  • Triazolopyridazine protein kinase modulators
    Patent number: 8071581
    Abstract: The present disclosure relates to triazolopyridazine protein kinase modulators of Formula (I), methods of using these compounds to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: December 6, 2011
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: Christopher Ronald Smith, Pierre-Yves Bounaud, Elizabeth Anne Jefferson, Patrick S. Lee, Eduardo Torres
  • Substituted triazole derivatives as oxytocin antagonists
    Patent number: 7875615
    Abstract: The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: January 25, 2011
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, David Ellis, Christopher Ronald Smith
  • TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS
    Publication number: 20100120739
    Abstract: The present disclosure relates to triazolopyridazine protein kinase modulators of Formula (I), methods of using these compounds to treat diseases mediated by kinase activity.
    Type: Application
    Filed: October 18, 2007
    Publication date: May 13, 2010
    Inventors: Christopher Ronald Smith, Pierre- Yves Bounaud, Elizabeth Anne Jefferson, Patrick S. Lee, Eduardo Torres
  • Substituted Triazole Derivatives As Oxytocin Antagonists
    Publication number: 20100063064
    Abstract: The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).
    Type: Application
    Filed: November 19, 2009
    Publication date: March 11, 2010
    Inventors: Alan Daniel Brown, David Ellis, Christopher Ronald Smith
  • Substituted triazole derivatives as oxytocin antagonists
    Patent number: 7649003
    Abstract: The present invention relates to a class of substituted 1,2,4-triazoles of formula (1) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: January 19, 2010
    Assignee: Pfizer Inc.
    Inventors: Alan Daniel Brown, David Ellis, Christopher Ronald Smith
  • BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS
    Publication number: 20090258855
    Abstract: The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.
    Type: Application
    Filed: October 18, 2007
    Publication date: October 15, 2009
    Inventors: Pierre-Yves Bounaud, Christopher Ronald Smith, Elizabeth Anne Jefferson
  • HETEROCYCLIC KINASE MODULATORS
    Publication number: 20090156594
    Abstract: The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.
    Type: Application
    Filed: May 21, 2008
    Publication date: June 18, 2009
    Applicant: SGX Pharmaceuticals, Inc.
    Inventors: Pierre-Yves Bounaud, Christopher Ronald Smith, Elizabeth A. Jefferson, Jorg Hendle, Patrick S. Lee, Angelina Marie Thayer, Gavin Charles Hirst
  • Substituted triazole derivatives as oxytocin antagonists
    Patent number: 7291640
    Abstract: The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: November 6, 2007
    Assignee: Pfizer Inc.
    Inventors: Alan Daniel Brown, David Ellis, Christopher Ronald Smith
  • Oxytocin inhibitors
    Patent number: 6914160
    Abstract: This invention relates to compounds of formula (I)
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: July 5, 2005
    Assignee: Pfizer Inc
    Inventors: Duncan Robert Armour, Andrew Simon Bell, Paul John Edwards, David Ellis, David Hepworth, Mark Llewellyn Lewis, Christopher Ronald Smith
  • Substituted triazole derivatives as oxytocin antagonists
    Publication number: 20050107382
    Abstract: The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).
    Type: Application
    Filed: September 20, 2004
    Publication date: May 19, 2005
    Inventors: Alan Daniel Brown, David Ellis, Christopher Ronald Smith